Despite the integration of PD-L1 inhibitors with chemotherapy, extensive-stage small-cell lung cancer (ES-SCLC) continues to portend a dismal prognosis, with a 5-year survival rate below 10%. Here, CD274 is linked to small cell lung carcinoma.